Sort by
Refine Your Search
-
, spanning a range of disease indications. Guided by this full-spectrum approach, we are committed to making CRISPR-based medicines a reality for people suffering from genetic diseases and to creating novel
-
courses with minor algorithmic components and primarily programming courses with a focus on bioinformatics methods. Such graduate courses seek experienced bioinformatics, biotech, and data science
-
-spectrum approach, we are committed to making CRISPR-based medicines a reality for people suffering from genetic diseases and to creating novel engineered cell therapies for various rare diseases
-
at Takeda provides medical support across the asset lifecycle, from early clinical development to marketed products, in three areas, Gastrointestinal and Inflammation, Neuroscience, and Rare Genetics
-
prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA
-
prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA
-
rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering
-
with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by
-
prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA
-
prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA